インタールイキン17阻害剤と早期の大変な心血管疾患

Maxime Raby^1,2, Frederic Balusson^1,3, Emmanuel Oger^1,3

¹Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de Recherche en 13 Santé, Environnement et Travail)-UMR_S 1085, Rennes, France.

JAMA dermatology

|September 3, 2025

まとめ

インテルルイキン17A (IL- 17A) 阻害剤の投与は,重大心血管疾患 (MACE) のリスクを有意に増加させない. この発見は様々な患者の心血管リスクレベルに当てはまりこれらの生物学的薬が心臓の健康に安全であることを示唆しています

科学分野:

心血管医学
皮膚科
免疫学

背景:

牛皮病に対する生物学的薬の心臓血管への影響は完全に理解されていません.
Tヘルパー17細胞経路の阻害は,動脈硬化性プラークを不安定化し,重大な心血管疾患 (MACE) を増加させる可能性があります.

研究の目的:

インタールイキン (IL) - 17A阻害剤の投与がMACEを誘発するかどうかを評価する.
腫瘍死滅因子 (TNF) -α阻害剤を比較基準として,IL- 17A阻害剤の発現とMACEとの関連性を評価する.

主な方法:

フランス国民健康保険データベース (2016-2021) を利用したケース・タイム・コントロール研究.
IL- 17A阻害剤 (セクキヌマブ,イクセキズマブ,ブロダルマブ) またはTNF- α阻害剤 (アダリムマブ,エタンセプト) を投与開始した患者も含まれています.
開始後の6ヶ月間のMACEリスクの評価は,以前の6ヶ月間の基準期間と比較した.

主要な成果:

IL- 17A阻害剤を投与した34,241人の患者で,381人のMACEを分析した.
TNFα阻害剤と比較して,IL- 17A阻害剤の投与開始は,MACE (OR,1. 40 [95% CI,0. 77-2. 54]) と有意な関連性を示さなかった.
結果は,感度分析と患者の心血管リスクレベルにおいて一貫していた.

結論:

MACEとIL- 17A阻害剤の発症との間に有意な関連性は見つかりませんでした.
この研究では,IL- 17A阻害剤は,牛皮病患者の心血管リスク増加と関連していないことが示されています.
控えめなリスクの上昇は完全に排除できないので,継続的なモニタリングが必要である.

さらに関連する動画

15:15

Flow Cytometry Analysis of Immune Cells Within Murine Aortas

Published on: July 1, 2011

34.8K

09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

1.8K

関連する概念動画

01:24

T Cell Types and Functions

1.4K

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...

1.4K

01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...

01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...

01:18

Endocarditis III: Medical Management

Infective endocarditis management involves a multifaceted approach encompassing infection prevention, lifestyle modifications, pharmacological therapy, and surgical management.Infection Prevention:Hand Hygiene: Thorough handwashing is crucial to prevent the spread of infection. Hand hygiene should be performed regularly, especially before and after using the restroom.Oral Hygiene: Good oral hygiene is essential. It includes brushing teeth immediately after waking up and before bed, flossing...

01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

505

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

505

01:27

Psychoneuroimmunology: Cardiovascular Disease

Psychoneuroimmunology (PNI) is a multidisciplinary field that examines how psychological factors, particularly stress, interact with the immune system and impact physical health. Research in PNI has shown that chronic or traumatic stress can disrupt both the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. These disruptions contribute to serious health conditions, including cardiovascular diseases.
A key area of focus in PNI is the relationship between stress and coronary...

関連する実験動画